Calliditas today announced an exclusive in-licensing deal regarding Budenofalk 3mg oral capsule for the treatment of autoimmune hepatitis (AIH) in the US. Total deal value amounts to roughly USD 45 million. We view today’s news as a logical step for Calliditas in its strategy to self-commercialize orphan assets in the US market.